CLINICAL_TRIALS
trial_result
· 2016-11-15
Clinical Trial Update: IMCgp100 in Advanced Unresectable Melanoma [EARLY_Phase 1]
Summary
The update reports the completion of an early-phase (Phase 1) trial of IMCgp100 (tebentafusp) in advanced, unresectable melanoma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Pennsylvania | Conditions: Melanoma, Advanced Disease | EARLY_Phase 1 | Status: COMPLETED